Australia needs a prioritised national research strategy for clinical trials in a pandemic: Lessons learned from COVID-19

Asha C. Bowen; Steven Y.C. Tong; Joshua S. Davis

doi:10.5694/mja2.51143

Australia needs a prioritised national research strategy for clinical trials in a pandemic: Lessons learned from COVID-19

Asha C. Bowen, Steven Y.C. Tong, Joshua S. Davis

Global and Tropical Health

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	56-58.e1
Number of pages	3
Journal	Medical Journal of Australia
Volume	215
Issue number	2
DOIs	https://doi.org/10.5694/mja2.51143
Publication status	Published - Jul 2021

Access to Document

10.5694/mja2.51143

Cite this

@article{33ba620d337946a1b15c43ef3cb82c25,

title = "Australia needs a prioritised national research strategy for clinical trials in a pandemic: Lessons learned from COVID-19",

keywords = "Clinical trials as topic, COVID-19, Infectious diseases, Public health, Respiratory tract infections",

author = "Bowen, {Asha C.} and Tong, {Steven Y.C.} and Davis, {Joshua S.}",

note = "Funding Information: To find effective therapeutic options for COVID‐19, various approaches to coordination and prioritisation of clinical research have been taken globally. There are more than 3000 relevant RCTs now registered. Among these, the key practice‐changing trials have been well coordinated, pragmatic, publicly supported by government, and funded by national research agencies. The standout examples are the Randomised Evaluation of COVID‐19 Therapy (RECOVERY) trial in the United Kingdom; the “Solidarity” clinical trial for COVID‐19 treatments, run by the World Health Organization (WHO); the Adaptive COVID‐19 Treatment Trial (ACTT) in the United States; and the Randomised, Embedded, Multi‐factorial, Adaptive Platform Trial for Community‐Acquired Pneumonia (REMAP‐CAP), which involves participating sites in 21 countries. In addition, the prior development of national clinical research networks and infrastructure for improved patient care has strengthened pandemic responsiveness. For example, the UK National Institute for Health Research, with a hospital‐based trial infrastructure of clinical research units, was recruiting > 2000 patients per day to RCTs before COVID‐19. When COVID‐19 trials were prioritised in the UK, the existing infrastructure was ready to support pragmatic studies such as RECOVERY and REMAP‐CAP. Almost 40 000 participants have been randomised in RECOVERY, and the UK has been the best recruiting nation globally for REMAP‐CAP (with > 4400 of > 6000 participants recruited). 3 4 5 6 7 8 9 5 8 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = jul,

doi = "10.5694/mja2.51143",

language = "English",

volume = "215",

pages = "56--58.e1",

journal = "Medical Journal of Australia",

issn = "0025-729X",

publisher = "Australasian Medical Publishing Company",

number = "2",

}

TY - JOUR

T1 - Australia needs a prioritised national research strategy for clinical trials in a pandemic

T2 - Lessons learned from COVID-19

AU - Bowen, Asha C.

AU - Tong, Steven Y.C.

AU - Davis, Joshua S.

N1 - Funding Information: To find effective therapeutic options for COVID‐19, various approaches to coordination and prioritisation of clinical research have been taken globally. There are more than 3000 relevant RCTs now registered. Among these, the key practice‐changing trials have been well coordinated, pragmatic, publicly supported by government, and funded by national research agencies. The standout examples are the Randomised Evaluation of COVID‐19 Therapy (RECOVERY) trial in the United Kingdom; the “Solidarity” clinical trial for COVID‐19 treatments, run by the World Health Organization (WHO); the Adaptive COVID‐19 Treatment Trial (ACTT) in the United States; and the Randomised, Embedded, Multi‐factorial, Adaptive Platform Trial for Community‐Acquired Pneumonia (REMAP‐CAP), which involves participating sites in 21 countries. In addition, the prior development of national clinical research networks and infrastructure for improved patient care has strengthened pandemic responsiveness. For example, the UK National Institute for Health Research, with a hospital‐based trial infrastructure of clinical research units, was recruiting > 2000 patients per day to RCTs before COVID‐19. When COVID‐19 trials were prioritised in the UK, the existing infrastructure was ready to support pragmatic studies such as RECOVERY and REMAP‐CAP. Almost 40 000 participants have been randomised in RECOVERY, and the UK has been the best recruiting nation globally for REMAP‐CAP (with > 4400 of > 6000 participants recruited). 3 4 5 6 7 8 9 5 8 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/7

Y1 - 2021/7

KW - Clinical trials as topic

KW - COVID-19

KW - Infectious diseases

KW - Public health

KW - Respiratory tract infections

UR - http://www.scopus.com/inward/record.url?scp=85108211718&partnerID=8YFLogxK

U2 - 10.5694/mja2.51143

DO - 10.5694/mja2.51143

M3 - Article

C2 - 34145568

AN - SCOPUS:85108211718

SN - 0025-729X

VL - 215

SP - 56-58.e1

JO - Medical Journal of Australia

JF - Medical Journal of Australia

IS - 2

ER -

Australia needs a prioritised national research strategy for clinical trials in a pandemic: Lessons learned from COVID-19

Access to Document

Other files and links

Cite this